Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]

Source: ClinicoEconomics and Outcomes Research - Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research